COVID-19 studies for: C19 studies:  HC QHC Q Vitamin DVitamin D IvermectinIVM LY-CoVLY REGN-COV2REGN RemdesivirRMD ZincZn
HC Q study #39
Source   PDF   Share   Tweet
See all 155 studies
Late treatment study
Kim et al., medRxiv, doi:10.1101/2020.05.13.20094193 (Preprint)
Treatment Response to Hydroxych loroquine, Lopinavir/Ritonavir, and Antibiotics for Moderate COVID 19: A First Report on the Pharmacological Outcomes from South Korea
Retrospective of 97 moderate cases. Time to viral clearance significantly shorter for HC Q+antibiotic. Preprint withdrawn pending peer review.
hospitalization time, ↓51.0%, p=0.01
time to viral-, ↓56.0%, p=0.005
Source   PDF   Share   Tweet
See all 155 studies
Please send us corrections, updates, or comments.